Recently, Pearson et al. showed that NF1 mutations were frequently acquired in breast cancer at progression and were associated with shorter survival in hormone receptor-positive breast cancers relapsing during adjuvant endocrine therapy [43]. This evidence concerns the gene NF1 and breast cancer.